SPECIAL AHA RECAP focusing on seven studies: ZEUS & Ziltivekima; HORIZON & Pelacarsen; OPTIMAL-STROKE & BP Control; STREAM & Statin Therapy; OPTIMA-DIABETES & BP Control Through Yoga, OptimPacing & Left Bundle-Branch Pacing; COAST-AF & Ablation

In this special edition of the View, Dr. Eagle looks at seven studies presented at the recent American Heart Association Conference that could have immediate effects on your practice. First, he discusses ZEUS: Interleukin-6 Inhibition With Ziltivekimab For High-Risk Patients With ASCVD, CKD and Systemic Inflammation, followed by Lp(a) HORIZON: Pelacarsen vs. Placebo in Patients With High Lp(a). Next, Dr. Eagle covered the OPTIMAL-STROKE trial that investigated whether intensive BP control targeting a systolic BP of 120 mm Hg or less in patients with elevated BP and previous ischemic stroke or TIA reduced the risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or hospitalization for unstable angina or heart failure, then discussed STREAM, a trial that added new insights into statin therapy treatment. Additionally, Dr. Eagle summarized the OPTIMAL-DIABETES trial that addressed intensive blood pressure (BP) lowering through yoga-based cardiac rehab. Finally, Dr. Eagle discussed the international, multicenter OptimPacing trial that investigated if left bundle-branch pacing was superior to right ventricular pacing in reducing the risk of death from any cause, heart failure (HF) hospitalization, or pacing-induced cardiomyopathy, and concluded with a look at COAST-AF, that shed light on ablation-related procedures or medical treatment of patients after atrial fibrillation (AFib) ablation.

Get ACC's full coverage of the AHA conference here.

Subscribe to Eagle's Eye View